Kohei shitara (@KoheiShitara) / X

ASCO #GI22: Gastric and esophageal cancers, HER2-targeted therapy, immunotherapy, ADCs

Ravi Jaiswal, MD (@RaviJaiswal___) / X

Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert

Kohei shitara (@KoheiShitara) / X

Kohei Shitara, MD @KoheiShitara @theNCI @NCIResearchCtr #ASCOGI21 #GastrointestalCancer #GICancer #Cancer #Research P

Kohei shitara (@KoheiShitara) / X

Kohei shitara (@KoheiShitara) / X

Margherita Ambrosini (@margheambro1) / X

Kohei shitara (@KoheiShitara) / X

Ryan Moy (@RyanMoyMDPhD) / X